Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published online Oct. 23 in JAMA Otolaryngology-Head & Neck Surgery. Richard G. Chiu, ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Between Sept 27, 2021, and ...

Please provide your email address to receive an email when new articles are posted on . Nasal polyp and congestion scores dropped more with stapokibart vs. placebo. Overall nasal symptoms, sense of ...

Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...